Lancet reports the results of a randomized controlled trial comparing prednisone alone to prednisone combined with either methotrexate (MTX) or cyclosporine (CyA) in new-onset juvenile dermatomyositis (JDM).

A prospective, international observational study of systemic sclerosis patients enrolled in the Digital Ulcers Outcome (DUO) Registry: Patients were required to have ≥3 follow-up visits over at least a 2 year observation period between 2008-2013.

MedPage Today reports that the Centers for Medicare & Medicaid Services (CMS) has issued a final rule governing payment for hip and knee replacements for Medicare patients this week that includes several concessions to stakeholders, such as delaying implementation from early 2016 to later in

A thoughtful perspective on the purpose, focus and cost of guideline efforts in rheumatology has been published in the journal Rheumatology.

Cacoub et al review the common entity cryoglobulinemic vasculitis (CryoVas) in the current issue of the American Journal of Medicine.

This small-vessel vasculitis involves the skin, joints, and potentially other organs, including the peripheral nervous system or the kidneys.

Furie and coworkers presented the results of a 52-week phase II trial of anifrolumab (ANIFR), a type I interfernon (IFN) receptor antagonist in patients with lupus (SLE).

Clements et al presented the results of their Scleroderma Lung Study II wherein PSS patients with interstitial lung disease were randomized to receive either 3 grams daily of mycopheonolate or 2mg/kg/day of cyclophosphamide.

Certain serologic and clinical features can help predict a chronic disease course among children with juvenile idiopathic inflammatory myopathies (JIIM), a large registry study showed.

Biosimilars are in the news and will be prominently on parade at next week's ACR meeting in San Francisco. Biosimilars are similar to, but not the same as, innovator biologics.

To assess the prevalence and magnitude of healthcare costs associated with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in the USA, researchers analyzed adminstrative data from Truven Health MarketScan Commercial and Medicare Supplemental databases.

A team of Japanese investigators examine 126 patients with ANCA-associated renal vasculitis to see if ANCA levels would predict disease relapse.

A comparison of mycophenolate mofetil (MMF) and low-dose cyclophosphamide IV (CYC) in the treatment of lupus nephritis (LN) was examined in 173 patients with class III, IV, or V LN.

Healio.com reports that pregnant women with APL antibodies and who took Plaquenil (HCQ or hydroxychloroquine) had better pregnancy outcomes than those who did not.

Patients in the U.S. with myositis who are positive for the anti-MDA5 autoantibody are at high risk for developing interstitial lung disease (ILD), a retrospective study found.

A study from the Taiwan National Health Insurance examined 2023 patients with new diagnoses of dermatomyositis or polymyositis and population controls and examined the frequency of Herpes zoster.

Healio reported the newly announced grant recipients from the Lupus Foundation of America.

Diffuse alveolar hemorrhage (DAH) is a rare but catastrophic complication of systemic lupus erythematosus. Presentations are usually acute and the potential for significant morbidity and mortality risk mandates early diagnosis and aggressive interventions.

The PROMISSE (Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus) study has revealed several important lessons in lupus care.

October is Raynaud's Awareness Month according to the Raynaud's Association (http://www.raynauds.org), and a whopping 80 percent of sufferers are not aware they have the disorder and do not seek treatment.

The Wall Street Journal reports that new drug development offers hope for people with idiopathic pulmonary fibrosis, a rare, progressive fibrosing lung disorder that affects nearly 200,000 Americans, mostly middle-aged and older adults.